Abstract
Background Substance use disorders (SUDs) are pressing global public health problems. Executive functions (EFs) are prominently featured in mechanistic models of addiction. However, there remain significant gaps in our understanding of EFs in SUDs, including the dimensional relationships of EFs to underlying neural circuits, molecular biomarkers, disorder heterogeneity, and functional ability. To improve health outcomes for people with SUDs, interdisciplinary clinical, preclinical and health services research is needed to inform policies and interventions aligned with biopsychosocial models of addiction. Here, we introduce Cognitive Dysfunction in the Addictions (CDiA), an integrative team-science and translational research program, which aims to fill these knowledge gaps and facilitate research discoveries to enhance treatments for people living with SUDs.
Methods The CDiA Program comprises seven complementary interdisciplinary projects that aim to progress understanding of EF in SUDs and investigate new biological treatment approaches. The projects draw on a diverse sample of adults aged 18-60 (target N=400) seeking treatment for addiction, who are followed prospectively over one year to identify EF domains crucial to recovery. Projects 1-3 investigate SUD symptoms, brain circuits, and blood biomarkers and their associations with both EF domains (inhibition, working memory, and set-shifting) and functional outcomes (disability, quality of life). Projects 4 and 5 evaluate interventions for addiction and their impacts on EF: a clinical trial of repetitive transcranial magnetic stimulation and a preclinical study of potential new pharmacological treatments in rodents. Project 6 links EF to healthcare utilization and is supplemented with a qualitative investigation of EF-related barriers to treatment engagement for those with substance use concerns. Project 7 uses innovative whole-person modeling to integrate the multi-modal data generated across projects, applying clustering and deep learning methods to identify patient subtypes and drive future cross-disciplinary initiatives.
Discussion The CDiA program has promise to bring scientific domains together to uncover the diverse ways in which EFs are linked to SUD severity and functional recovery. These findings, supported by emerging clinical, preclinical, health service, and whole-person modeling investigations, will facilitate future discoveries about cognitive dysfunction in addiction and could enhance the future clinical care of individuals seeking treatment for SUDs.
Scope statement Substance use disorders (SUDs) are a leading contributor to psychiatric morbidity, mortality, and functional impairment. Cognitive dysfunction contributes substantially to this impairment, and plays a prominent role in causal models of addiction. Executive dysfunction in particular is linked to the onset and persistence of SUDs. Large-scale, multidisciplinary efforts are necessary to elucidate the nature and course of cognitive deficits and associated functional outcomes in SUDs. The Cognitive Dysfunction in the Addictions (CDiA) integrative, translational research program undertakes to advance the study of cognitive dysfunction in SUDs, with a focus on impairments in executive function. The Program incorporates preclinical, clinical, and health systems level investigation. The proposed investigations are well positioned to determine how experimental findings translate from humans to animals (reverse translational approach), as well as how preclinical findings will translate into the development of novel treatment avenues.
Competing Interest Statement
DMB received research support and in-kind equipment support for an investigator-initiated study from Brainsway Ltd. He was the site principal investigator for three sponsor-initiated studies for Brainsway Ltd. He also received in-kind equipment support from Magventure for two investigator-initiated studies. He received medication supplies for an investigator-initiated trial from Indivior. He is a scientific advisor for Sooma Medical. He is the Co-Chair of the Clinical Standards Committee of the Clinical TMS Society (unpaid). TDP and ES are listed as inventors on patents covering the use of molecules proposed to be tested in the described study. TDP also acts as the Director of Preclinical Research and Development of DAMONA Pharmaceuticals, a spin-off company from CAMH aiming at leading the licensed technology to the clinical for reduction of cognitive deficits in brain disorders. ES acts as the CSO and Founder of DAMONA Pharmaceuticals.
Clinical Trial
NCT06299787
Funding Statement
The CDiA Program is supported by a Discovery Fund grant administered through the Centre for Addiction & Mental Health Foundation. The authors gratefully acknowledge the CDiA Program Study Group for their contributions to this research. The authors thank the participants of the CDiA Program. We also thank the CDiA Lived Expertise Research Advisory, CDiA Scientific Advisory Board, and the clinical team members of the CAMH Addictions Program for their contributions and support of this work. YSN is supported by a Koerner New Scientist Award and a Paul Garfinkel Catalyst Award administered by the CAMH Foundation. DF is supported by CIHR, the Koerner Family Foundation and the Krembil Foundation. DMB receives research support from CIHR, NIMH (R01MH112815;R21MH128815; R01MH1192850), Brain Canada and the Temerty Family through the CAMH Foundation and the Campbell Family Research Institute. The neurophysiological analysis for Project 5 was partly supported by the Labatt Family Network for Research on the Biology of Depression.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Research Ethics Board (REB) at the Centre for Addiction and Mental Health (CAMH), REB #: 010/2021. The participants will provide written informed consent to take part in the study. Animal procedures were reviewed and approved by CAMH Animal Care Committee, in accordance with the guidelines of the Canadian Council for Animal Care.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Writer updated name of Author from LeFoll to Le Foll. Updated COI for BF
Data Availability
This is a protocol paper, which does not include any data.
